Cargando…
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
Following the demonstration of efficacy, tolerability and quality-of-life benefits of raltitrexed ('Tomudex'), principally in advanced colorectal but also in other cancers, an extensive evaluation of combination therapy with other agents in patients with colorectal and other tumour types i...
Autor principal: | Blackledge, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149719/ https://www.ncbi.nlm.nih.gov/pubmed/9579853 |
Ejemplares similares
-
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.
por: Woll, P. J., et al.
Publicado: (1997) -
Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).
por: Judson, I., et al.
Publicado: (1998) -
Mature results from three large controlled studies with raltitrexed ('Tomudex').
por: Cunningham, D.
Publicado: (1998) -
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
por: Köhne, C. H., et al.
Publicado: (1998) -
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
por: Smith, I., et al.
Publicado: (1996)